e-learning
resources
Milan 2017
Sunday, 10.09.2017
Markers of COPD progression
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The comparison of eosinophilic and non-eosinophilic stable COPD patients
G. Karadeniz (IZMIR, Turkey)
Source:
International Congress 2017 – Markers of COPD progression
Session:
Markers of COPD progression
Session type:
Thematic Poster
Number:
1088
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Karadeniz (IZMIR, Turkey). The comparison of eosinophilic and non-eosinophilic stable COPD patients. 1088
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Can NPT be used to distinguish eosinophilic inflammatory phenotypes in COPD?
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
The importance of eosinophilic inflammation in COPD exacerbations
Source: International Congress 2017 – COPD management
Year: 2017
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Pulmonary hypertension in eosinophilic
versus
noneosinophilic COPD
Source: ERJ Open Res, 7 (1) 00772-2020; 10.1183/23120541.00772-2020
Year: 2021
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
The rate of re-exacerbation in patients hospitalized with eosinophil and non-eosinophilic COPD relapses
Source: Virtual Congress 2020 – Phenotypes of obstructive diseases
Year: 2020
Airway inflammation in non-eosinophilic atopic asthma: comparisons with eosinophilic atopic asthma and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 733s
Year: 2005
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
COPD and asthma overlap with bronchiectasis
Source: Eur Respir Monogr 2018; 81: 167-185
Year: 2018
Inflammatory cell counts in induced sputum from non-allergic asthmatics and COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 317s
Year: 2004
Sputum analysis reveals eosinophilic inflammation in difficult-to-control asthma patients with low blood eosinophils and FENO.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Catabolic/anabolic balance in patients with COPD exacerbation
Source: Eur Respir J 2004; 24: Suppl. 48, 305s
Year: 2004
Is the unclassifiable obstructive airway more similar to asthma than COPD?
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
A study on the pulmonary function of patients with chronic eosinophilic pneumonia
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Care-continuity for COPD patients
Source: Annual Congress 2012 - Nursing led education and follow-up strategies: impact on readmission, self care and patient experiences
Year: 2012
COPD patients
Source: Eur Respir Monogr 2021; 90: 154-164
Year: 2021
Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Neutrophilic inflammation in severe asthmatics and COPD patients with the same severity of airway obstruction
Source: Eur Respir J 2002; 20: Suppl. 38, 505s
Year: 2002
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept